Transgenomic, Inc. (Transgenomic) provides products for the purification and analysis of nucleic acids used in the life sciences industry for research focused on molecular genetics and diagnostics. The Company also provides genetic variation analytical services to the medical research, clinical and pharmaceutical markets. Its products and services are categorized as Instrument Related Business and Laboratory Services. It has sold its products to customers in over 50 countries. Customers include numerous academic and medical institutions in the United States and abroad. In addition, its customers also include number of pharmaceutical, biotech and commercial companies both in the United States and abroad. In December 2010, the Company acquired Clinical Data, Inc.'s diagnostic business. ransgenomic, Inc. (www.transgenomic.com) is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company is the global leader in cardiac genetic testing with a family of innovative products, including its flagship C-GAAP test, designed to detect gene mutations which indicate cardiac disorders, or which can lead to serious adverse events. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthens its leadership in personalized medicine.

QIAGEN GmbH provides products for preanalytical sample preparation and molecular diagnostics solutions. It develops and markets consumable products and automated solutions to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. The company was founded in 1984 and is headquartered in Hilden, Germany.

John Wayne Cancer Institute is an American private company located in Santa Monica, CA. The firm operates cancer research institute.\nThe company says this about itself: Since 1981, the family of John Wayne has been committed to pioneering cancer research in memory of their father, who died of cancer. The courageous and dedicated researchers at the John Wayne Cancer Institute have made groundbreaking discoveries that have changed the way cancer is detected, diagnosed and treated around the world. Today the tradition of excellence continues as the Institute spearheads new research advances, while training the next generation of leaders in the fight against cancer through its renowned Surgical Oncology Fellowship Program. The Institute provides immediate hope to cancer patients everywhere.

PlexBio was established in May 2010 to design, gns, develops, and manufactures IVD products and instrumentations in ISO-certified facilities. In order to address the issue of rising healthcare costs and an increasing range of available tests, it is crucial for clinical and research labs to consider the cost of labor, sample volume, time, and maintenance when it comes to assay formats. Therefore, PlexBio aims to provide a cutting-edge multiplexing platform using patented Precision Image Code (π Code) MicroDisc technology to overcome this limitation. they are π Code Microdisc technology is currently the largest multiplexing platform, capable of generating around 16,000 circular image patterns.

Genecor, Inc. provides engineering services. The company is headquartered in Quebec City, Canada.

TwinStrand Biosciences improves the accuracy of DNA sequencing by >10,000 fold and allows detection of mutations that are invisible by other approaches, through its technology. Its technology, Duplex Sequencing, is based on research and has potential applications in a wide range of fields, including oncology, infectious disease, organ transplantation, reproductive and genetic health, and forensics.

Seoul National University Hospital (서울대학교병원) is one of the oldest and biggest hospitals in South Korea. It is a general and teaching hospital of Seoul National University's College of Medicine. Except SNUH Healthcare System Gangnam Center, all branches have an emergency department (ED).

Helmholtz-Zentrum für Infektionsforschung GmbH provides bio-medical research and development services. The firm engages in research projects focused on infection biology and its clinical application and practical implementation. It also specializes in the examination of pathogens that are either medically relevant or that can be used as models for the research of infections. Its research topics encompass bacterial and viral pathogens, immune response, and anti-infectives. The company was founded in 1965 and is headquartered in Braunschweig, Germany.

Lumigen, Inc. develops, manufactures and markets chemicals. It distributes chemiluminescent reagents for the clinical immunodiagnostics markets. The firm’s Life Diagnostics SPARCL Kits, Western Blotting, ELISA and Hydrogen Peroxide Detection. The company was founded by A. Paul Schaap in 1987 and is headquartered in Southfield, MI.

Quest Diagnostics Investments LLC, a subsidiary of Quest Diagnostics, Inc., is an American company specializing in medical laboratories.

Visible Genetics, Inc. manufactures and markets automated DNA sequencing systems and diagnostic kits. The company develops genotyping technology that employs DNA sequencing that enables the analysis in the clinical diagnostic laboratory of individual genetic variations. It was founded in 1993 and is headquartered in Toronto, Canada

Jiaohong Biology is used in the fields of precise diagnosis of tumours, nucleic acid detection of epidemic viruses, nucleic acid detection of animal and plant diseases, and food safety. It is a provider of molecular diagnostic technology research, development, and application services.

Hangzhou Ruipu Gene Technology Co., Ltd., established on 2015-06-18, Business scope includes gene technology,Genetic Diagnosis and Therapy,Biotechnology,Technology development of detection technology and computer software,technical consulting,Technical Services,technology transfer;Import and export of goods and technology(law,Except for items prohibited by administrative regulations,law,Projects that are restricted by administrative regulations can only be operated after obtaining a license);Production:biological reagent(In addition to drugs,Dangerous chemicals and the first category of precursor chemicals),medical instruments(one,two,Three categories);Sales:lab supplies,Instrumentation,Chemical raw materials and products(Removal of Precursor Chemicals and Hazardous Chemicals),test reagent,Detection Reagent,medical instruments(one,two,Three categories),Scientific research equipment and consumables,laboratory equipment.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Founded in 1993 by Andrew Cousin, Amersham Corp. is a private equity firm located in Louisville, Colorado with additional offices in California, Florida, Texas and China.

Incyte is a drug discovery and development company which hopes to build a proprietary product pipeline of novel small molecule drugs. Incyte's product pipeline is currently focused on oncology and inflammation and includes compounds in various stages of development. Through partnerships with [Novartis](/organization/novartis), [Eli Lilly](/organization/eli-lilly), and [Pfizer](/organization/pfizer), Incyte intends to promote the clinical development and global commercialization of several of their compounds.

NantOmics develops cloud-based molecular profiling tools that help guide cancer patients. It is a molecular diagnostics company, develops molecular profiling solutions that identify personalized treatment options for cancer patients and their providers at the point of care. It offers GPS Cancer test that provides a molecular profile of patient’s cancer to inform personalized treatment strategies to oncologists and OncoPlexDx Targeted Proteomic panel that provides quantitative protein biomarker information for multiple clinically relevant proteins yielding insights into the biology driving the growth of the patient’s cancer. Patrick Soon-Shiong founded NantOmics in 2012, with its headquarters in Culver City, California. NantOmics operates as a subsidiary of NantWorks.

Develops and manufactures agricultural and noncrop products

Cambridge University Technical Services Ltd., part of University of Cambridge, is a British company located in Cambridge. The firm provides consulting services. It was founded in 2006.